

Samantha Pozzi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1397424/publications.pdf>

Version: 2024-02-01

104
papers

3,295
citations

159585

30
h-index

149698

56
g-index

105
all docs

105
docs citations

105
times ranked

5086
citing authors

#	ARTICLE	IF	CITATIONS
1	ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 805-811.	1.6	256
2	Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. <i>Journal of Clinical Investigation</i> , 2008, 118, 491-504.	8.2	202
3	The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells <i>In vitro</i> and <i>In vivo</i> . <i>Clinical Cancer Research</i> , 2009, 15, 4028-4037.	7.0	200
4	Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 5124-5129.	7.1	196
5	Dual Inhibition of Akt/Mammalian Target of Rapamycin Pathway by <i>In vitro</i> Nanoparticle Albumin-Bound <i>In vivo</i> Rapamycin and Perifosine Induces Antitumor Activity in Multiple Myeloma. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 963-975.	4.1	156
6	5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 1718-1727.	4.1	154
7	MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. <i>Blood</i> , 2007, 110, 3744-3752.	1.4	144
8	A novel role for CCL3 (MIP-1 β) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function. <i>Leukemia</i> , 2011, 25, 1174-1181.	7.2	134
9	AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3 β activation and RNA polymerase II inhibition. <i>Oncogene</i> , 2010, 29, 2325-2336.	5.9	120
10	A High-Affinity Fully Human Anti-IL-6 mAb, 1339, for the Treatment of Multiple Myeloma. <i>Clinical Cancer Research</i> , 2009, 15, 7144-7152.	7.0	103
11	Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study. <i>Haematologica</i> , 2008, 93, 398-404.	3.5	92
12	High-Dose Zoledronic Acid Impacts Bone Remodeling with Effects on Osteoblastic Lineage and Bone Mechanical Properties. <i>Clinical Cancer Research</i> , 2009, 15, 5829-5839.	7.0	90
13	Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients. <i>Leukemia and Lymphoma</i> , 2007, 48, 56-64.	1.3	86
14	Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis. <i>British Journal of Haematology</i> , 2013, 163, 40-46.	2.5	80
15	Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. <i>Annals of Oncology</i> , 2010, 21, 1486-1491.	1.2	79
16	Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab era. <i>Haematologica</i> , 2014, 99, 125-130.	3.5	77
17	The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2337.	4.1	67
18	Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma. <i>Leukemia</i> , 2009, 23, 961-970.	7.2	65

#	ARTICLE	IF	CITATIONS
19	In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma. <i>Bone</i> , 2013, 53, 487-496.	2.9	65
20	The Role of Bisphosphonates in Multiple Myeloma: Mechanisms, Side Effects, and the Future. <i>Oncologist</i> , 2011, 16, 651-662.	3.7	62
21	Antimyeloma Activity of a Multitargeted Kinase Inhibitor, AT9283, via Potent Aurora Kinase and STAT3 Inhibition Either Alone or in Combination with Lenalidomide. <i>Clinical Cancer Research</i> , 2011, 17, 3259-3271.	7.0	59
22	Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients. <i>Cancer</i> , 2007, 109, 2077-2082.	4.1	50
23	From Osteoclast Differentiation to Osteonecrosis of the Jaw: Molecular and Clinical Insights. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4925.	4.1	48
24	Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2017, 22, 827-840.	4.9	44
25	Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma. <i>Cancer</i> , 2007, 110, 121-128.	4.1	41
26	Absolute Monocyte Count and Lymphocyte-Monocyte Ratio Predict Outcome in Nodular Sclerosis Hodgkin Lymphoma: Evaluation Based on Data From 1450 Patients. <i>Mayo Clinic Proceedings</i> , 2015, 90, 756-764.	3.0	39
27	Prognostic relevance of serum λ 2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study. <i>Haematologica</i> , 2007, 92, 1482-1488.	3.5	38
28	Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: results of a large multicenter study involving 990 patients. <i>Hematological Oncology</i> , 2017, 35, 561-566.	1.7	36
29	Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study. <i>Haematologica</i> , 2008, 93, 1335-1342.	3.5	35
30	Cytokine Release Syndrome Associated with T-Cell-Based Therapies for Hematological Malignancies: Pathophysiology, Clinical Presentation, and Treatment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7652.	4.1	33
31	Acquired haemophilia in HIV negative, HHV-8 positive multicentric Castleman's disease: a case report. <i>European Journal of Haematology</i> , 2003, 70, 181-182.	2.2	29
32	Risk of Second Primary Malignancy in Breast Cancer Survivors: A Nested Population-Based Case-Control Study. <i>Journal of Breast Cancer</i> , 2015, 18, 378.	1.9	25
33	The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines. <i>Cancer Biology and Therapy</i> , 2016, 17, 1094-1106.	3.4	25
34	Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomas. <i>Leukemia Research</i> , 2013, 37, 619-623.	0.8	24
35	A simple and safe nomogram for the management of oral anticoagulation prior to minor surgery. <i>International Journal of Laboratory Hematology</i> , 2003, 25, 127-130.	0.2	21
36	Analysis of Frequency and Risk Factors for Developing Bisphosphonate Associated Osteonecrosis of the Jaw. <i>Blood</i> , 2005, 106, 5057-5057.	1.4	20

#	ARTICLE	IF	CITATIONS
37	Citarinostat and Momelotinib co-target HDAC6 and JAK2/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2020, 25, 370-387.	4.9	17
38	Ruxolitinib combined with vorinostat suppresses tumor growth and alters metabolic phenotype in hematological diseases. <i>Oncotarget</i> , 2017, 8, 103797-103814.	1.8	17
39	THERAPY-RELATED MYELOID NEOPLASM IN NON-HODGKIN LYMPHOMA SURVIVORS. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2011, 3, e2011065.	1.3	15
40	The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines. <i>Hematological Oncology</i> , 2015, 33, 166-175.	1.7	15
41	Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2016, 101, e196-e199.	3.5	15
42	NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 1597-1606.	4.1	14
43	Activity of BKM120 and BEZ235 against Lymphoma Cells. <i>BioMed Research International</i> , 2015, 2015, 1-12.	1.9	13
44	Cell-Penetrating CaCO ₃ Nanocrystals for Improved Transport of NVP-BEZ235 across Membrane Barrier in T-Cell Lymphoma. <i>Cancers</i> , 2018, 10, 31.	3.7	13
45	Bisphosphonates associated osteonecrosis of the jaw: A long-term follow-up of a series of 35 cases observed by GISL and evaluation of its frequency over time. <i>American Journal of Hematology</i> , 2009, 84, 850-852.	4.1	12
46	Front-Line Brief Chemo-Immunotherapy Rituximab (R)-FND + Rituximab Consolidation ± Rituximab Maintenance in Elderly Patients with Untreated Advanced Stage Follicular Lymphoma (FL): First Interim Analysis of a Prospective Randomized Study (ML17638). <i>Blood</i> , 2007, 110, 1278-1278.	1.4	10
47	Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study. <i>Leukemia and Lymphoma</i> , 2017, 58, 552-559.	1.3	9
48	RGB 286638, a Novel Multi-Targeted Small Molecule Inhibitor, Induces Multiple Myeloma (MM) Cell Death through Abrogation of CDK-Dependent and Independent Survival Mechanisms. <i>Blood</i> , 2008, 112, 2759-2759.	1.4	9
49	AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor with Potent Activity Against Aurora Kinase and STAT3 In Combination with Lenalidomide Results In Synergistic Anti-Myeloma Activity. <i>Blood</i> , 2010, 116, 2994-2994.	1.4	8
50	Bisphosphonates and Atypical Femoral Fractures. <i>New England Journal of Medicine</i> , 2010, 363, 1083-1085.	27.0	7
51	Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma. <i>Cancer</i> , 2009, 115, 1906-1913.	4.1	6
52	Defining the best cutoff value for lymphopenia in diffuse large B cell lymphoma treated with immunochemotherapy. <i>British Journal of Haematology</i> , 2014, 167, 133-136.	2.5	6
53	Restoration of Bone Balance Via Activin A Inhibition Results in Anti-Myeloma Activity. <i>Blood</i> , 2008, 112, 645-645.	1.4	6
54	Management of Adverse Events and Supportive Therapy in Relapsed/Refractory Multiple Myeloma. <i>Cancers</i> , 2021, 13, 4978.	3.7	6

#	ARTICLE	IF	CITATIONS
55	Pazopanib-related secondary polycythemia in metastatic myxofibrosarcoma: A case report and review of the literature. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 766-770.	0.9	5
56	Role of thalidomide in previously untreated patients with multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1569-1580.	2.4	4
57	A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up. <i>Acta Haematologica</i> , 2017, 137, 7-14.	1.4	4
58	The prognostic role of end of treatment FDG-PET-CT in patients with diffuse large B cell lymphoma can be improved by considering it with absolute monocyte count at diagnosis. <i>Leukemia and Lymphoma</i> , 2019, 60, 1958-1964.	1.3	4
59	Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma. <i>Hematological Oncology</i> , 2020, 38, 439-445.	1.7	4
60	AT7519, a Novel Small Molecule Multi-Cyclin Dependent Kinase Inhibitor, Induces Apoptosis in Multiple Myeloma VIA GSK3 β . <i>Blood</i> , 2008, 112, 251-251.	1.4	4
61	Molecular Profiling of Extramedullary and Medullary Plasmacytomas. <i>Blood</i> , 2008, 112, 5111-5111.	1.4	4
62	Low-Molecular-Weight Heparin for Vertebral Artery Dissection. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2002, 8, 179-181.	1.7	3
63	The potential of pralatrexate as a treatment of peripheral T-cell lymphoma. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 711-718.	4.1	3
64	Promoting Osteoblastogenesis Using a Novel Dkk-1 Neutralizing Antibody in the Treatment of Multiple Myeloma Related Bone Disease. <i>Blood</i> , 2008, 112, 2739-2739.	1.4	3
65	Combination of Nab-Rapamycin and Perifosine Induces Synergistic Cytotoxicity and Antitumor Activity Via Autophagy and Apoptosis in Multiple Myeloma (MM). <i>Blood</i> , 2008, 112, 3663-3663.	1.4	3
66	The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Potent and Selective Cytotoxicity against CD138 Positive Multiple Myeloma Cells in Vitro and in Vivo.. <i>Blood</i> , 2008, 112, 1716-1716.	1.4	3
67	Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter Follidela Study. <i>Cancers</i> , 2022, 14, 654.	3.7	3
68	The monoclonal antibody nBT062 conjugated to maytansinoids has potent and selective cytotoxicity against CD138 positive multiple myeloma cells in vitro and in vivo. <i>Nature Precedings</i> , 2008, , .	0.1	2
69	Absolute monocyte count at diagnosis could improve the prognostic role of early <sc>FDG</sc>â€<sc>PET</sc> in classical Hodgkin lymphoma patients. <i>British Journal of Haematology</i> , 2018, 180, 600-602.	2.5	2
70	Selective Inhibition of HDAC6 with a New Prototype Inhibitor (ACY-1215) Overcomes Bortezomib Resistance In Multiple Myeloma (MM). <i>Blood</i> , 2010, 116, 2997-2997.	1.4	2
71	Delineation of Canonical and Non-Canonical NF- κ B Pathways in Multiple Myeloma: Therapeutic Implications.. <i>Blood</i> , 2007, 110, 670-670.	1.4	2
72	Biological effects of Atra and Arsenic Trioxide on short term cultures of non-M3 leukemic blasts. <i>Leukemia and Lymphoma</i> , 2005, 46, 257-263.	1.3	1

#	ARTICLE	IF	CITATIONS
73	Dialysisâ€dependent renal failure at diagnosis continues to be associated with very poor outcome in multiple myeloma â€ response to <sc>M</sc>urphy <i>etÂal</i>. British Journal of Haematology, 2014, 165, 892-892.	2.5	1
74	Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ). , 2014, , 153-165.		1
75	Brief Chemoimmunotherapy Rituximab (R)-FND Â± R Maintenance as First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Preliminary Analysis of a Prospective Randomized III Trial. Blood, 2008, 112, 834-834.	1.4	1
76	Molecular Profiling of Extramedullary and Medullary Plasmacytomas.. Blood, 2009, 114, 1806-1806.	1.4	1
77	CYC065, a Potent Derivative of Seliciclib Is Active In Multiple Myeloma In Preclinical Studies. Blood, 2010, 116, 2999-2999.	1.4	1
78	Lenalidomide In Combination with the Activin Receptor Type II Murine Fc Protein RAP-011: Preclinical Rationale for a Novel Anti-Myeloma Strategy. Blood, 2010, 116, 4075-4075.	1.4	1
79	Increased Sclerostin Secretion in Multiple Myeloma Results in Stimulation of Osteoclastogenesis and Inhibition of Osteoblastogenesis. Blood, 2011, 118, 1819-1819.	1.4	1
80	In Vitro Combination of Bortezomib with Enzastaurin or Lenalidomide Enhances the Cytotoxicity in B-Cell Lymphoma Cell Lines.. Blood, 2012, 120, 2754-2754.	1.4	1
81	Final Results Of a Phase II Study Of Lenalidomide In Combination With Rituximab For The Treatment Of Indolent Non Follicular Non Hodgkin Lymphoma. Blood, 2013, 122, 4383-4383.	1.4	1
82	Bortezomib and Plasma Cell Leukemia.. Blood, 2006, 108, 3546-3546.	1.4	1
83	AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor Induces Antimyeloma Activity Via Potent Aurora Kinase and STAT3 Inhibition.. Blood, 2009, 114, 3833-3833.	1.4	1
84	Disruption of DEPTOR/mTORC1/mTORC2 Signaling Cascade Using a Novel Selective mTOR Kinase Inhibitor AZD8055 Results In Growth Arrest and Apoptosis In Multiple Myeloma Cells. Blood, 2010, 116, 791-791.	1.4	1
85	Targeting Bruton's Tyrosine Kinase As a Novel Approach to Inhibit Osteoclast Function in Multiple Myeloma. Blood, 2011, 118, 2882-2882.	1.4	1
86	Preclinical Efficacy and Biological Effects of Venetoclax and Ixazomib in Combination in Lymphoma Cells. Blood, 2020, 136, 37-38.	1.4	1
87	High dose of Zoledronic acid inhibits both osteoclasts and osteoblasts in an In Vivo mouse model. Bone, 2008, 42, S63.	2.9	0
88	A concise review of lenalidomide therapy for follicular lymphoma. Expert Opinion on Orphan Drugs, 0, , 1-7.	0.8	0
89	Diffuse Large B-Cell Lymphomas (DLBCL) with Hepatitis-C Virus (HCV) Infection: Incidence, Clinical Outcome and Preliminary Results of Antiviral Treatments (AVT) after Chemotherapy.. Blood, 2006, 108, 2442-2442.	1.4	0
90	Rituximab (R) in Combination with Fludarabine (F) and Cyclophosphamide (C) in Relapsed Follicular Lymphoma (FL) Patients (pts).Final Results of FC + R Phase II Trial by the GISL.. Blood, 2006, 108, 2763-2763.	1.4	0

#	ARTICLE	IF	CITATIONS
91	Secondary Malignancies after Treatment of Aggressive Non-Hodgkin Lymphoma: A GISL Cohort Study on 1259 Patients.. Blood, 2007, 110, 522-522.	1.4	0
92	Multiple Myeloma Cell-Osteoblast Interaction Results in Impaired Bone Formation.. Blood, 2007, 110, 4764-4764.	1.4	0
93	Molecular Sequaele of Activin A-Dependent Osteoblast Inhibition in Myeloma.. Blood, 2009, 114, 1789-1789.	1.4	0
94	CCL3 Impairs Osteoblast Function Via Downregulation of Osteocalcin.. Blood, 2009, 114, 739-739.	1.4	0
95	Overcoming p53 Loss with a Multi-Targeted Small Molecule Inhibitor in Multiple Myeloma.. Blood, 2009, 114, 4915-4915.	1.4	0
96	Molecular Profiling of Extramedullary and Medullary Plasmacytomas Compared to Multiple Myeloma. Blood, 2010, 116, 4042-4042.	1.4	0
97	Relative Survival and Incidence Based Mortality of Diffuse Large B-Cell Lymphoma (DLBCL) in Rituximab Era: Population Based Study From Modena Cancer Registry (MCR). Blood, 2011, 118, 5185-5185.	1.4	0
98	Monocytosis Has Adverse Prognostic Significance and Impacts Survival in Patients with T-Cell Lymphomas.. Blood, 2012, 120, 2647-2647.	1.4	0
99	Prognostic Role of Serum Albumin Level in DLBCL before and during the Rituximab Era. Retrospective GISL Study over 738 Cases. Blood, 2014, 124, 5411-5411.	1.4	0
100	Prognostic Score Based on Clinical and Biochemical Surrogates of Disease Status in DLBCL Trated with Chemo-Immunotherapy. Blood, 2014, 124, 3027-3027.	1.4	0
101	Calcium-Carbonate Nanocapsules Improve the Efficacy of BEZ235 in Lymphoma a Cell Line: A Promising New Technology of Drug Delivery. Blood, 2015, 126, 4851-4851.	1.4	0
102	Neutrophil - Lymphocyte Ratio (NLR) at Diagnosis Is an Independent Prognostic Factor in Patients with Nodular Sclerosis Hodgkin Lymphoma: Results of a Large Multicenter Study Involving 990 Patients. Blood, 2015, 126, 3862-3862.	1.4	0
103	Neutrophil to Lymphocyte Ratio at Diagnosis Is an Independent Prognostic Factor in Diffuse Large B-Cell Lymphoma: Results of a Large Multicenter Study Involving 931 Patients. Blood, 2015, 126, 1465-1465.	1.4	0
104	Combination of Momelotinib and Citarinostat Show Strong Synergistic Effect in Lymphoid Cell Lines Co-Targeting JAK2/STAT3 and HDAC6. Blood, 2018, 132, 3506-3506.	1.4	0